Saturday 17 October 2026
Export TRIB’s income statement to Excel — free account
Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
8.03
0.10
+1.26%
Follow TRIB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.41 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 6 | 6 | 3 | 6 | 5 | 2 | 4 | 3 | 4 |
P/S ratio |
1.60 | 1.13 | 0.49 | 0.24 | 0.78 | 0.34 | 0.57 | 0.30 | 0.26 | 0.33 |
Altman Z-Score |
1.69 | 1.50 | 1.52 | 0.83 | 1.78 | 0.99 | 0.17 | (1.09) | (0.98) | (2.78) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.02 | 3.61 | 3.71 | 1.80 | 3.08 | (0.82) | (0.29) | (3.38) | (3.57) | (11.61) |
Beneish M-Score |
(4.06) | (3.84) | (3.15) | (3.97) | (3.57) | (3.11) | (4.25) | (5.03) | (3.15) | (4.29) |
P/Operating CF |
158.05 | 74.15 | 24.79 | (5.93) | 6.38 | 7.22 | 19.51 | 69.52 | 4.71 | (9.94) |
P/B ratio |
1.47 | 1.72 | 1.09 | 4.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
7.44 | 253.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1.76 | 1.49 | 1.02 | 1.19 | 1.51 | 1.12 | 1.62 | 1.42 | 1.80 | 3.31 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 1,873.92 | 13.44 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
17.16 | 15.97 | 13.76 | 19.81 | 6.47 | 7.89 | (110.04) | (6.97) | (26.42) | (24.41) |
EV/FCF |
(2.57) | (2.41) | (1.76) | (2.49) | (9.45) | (42.78) | (14.69) | (5.65) | (7.77) | (10.28) |
Quick Ratio |
3.94 | 3.69 | 3.11 | 1.92 | 1.85 | 0.42 | 1.29 | 1.17 | 0.66 | 0.12 |
Current Ratio |
5.28 | 5.30 | 4.92 | 3.67 | 3.08 | 0.72 | 2.69 | 2.60 | 1.28 | 0.25 |
Net Debt/EBITDA |
(0.48) | (1.12) | (3.23) | (4.46) | 23.46 | 7.82 | (3.86) | (2.45) | (4.82) | (9.92) |
Debt/Assets |
37.36% | 48.63% | 54.30% | 77.95% | 77.79% | 83.40% | 78.39% | 110.24% | 95.14% | 128.55% |
Debt/Equity |
0.86 | 1.44 | 1.87 | 21.68 | (45.71) | (310.84) | (33.18) | (2.74) | (2.79) | (1.88) |
Asset Turnover |
0.32 | 0.45 | 0.56 | 0.64 | 0.78 | 0.75 | 0.59 | 0.75 | 0.76 | 0.42 |
Operating CF/Net income |
(0.10) | (0.23) | (0.33) | (0.19) | (3.72) | 15.13 | 0.02 | 0.48 | 0.13 | 0.16 |
Capex/Depreciation |
(3.39) | (2.90) | (4.22) | (2.42) | (3.31) | (3.17) | (2.56) | (1.52) | (5.40) | (2.32) |
Interest Coverage |
(7.33) | (6.97) | (3.98) | (3.66) | 0.01 | 0.93 | (0.78) | (2.45) | (2.21) | (0.74) |
| (62.38%) | (46.31%) | (40.44%) | (118.58%) | (512.27%) | (68.95%) | 3,287.29% | 183.87% | 107.52% | 69.76% | |
| (32.82%) | (18.20%) | (12.82%) | (20.45%) | (4.89%) | 0.70% | (38.87%) | (31.70%) | (39.07%) | (35.86%) | |
ROIC |
(19.95%) | (23.21%) | (13.15%) | (16.66%) | 0.07% | 5.68% | (19.06%) | (44.62%) | (22.84%) | (16.99%) |
Return on Tangible Assets |
(82.74%) | (41.45%) | (29.68%) | (47.22%) | (9.86%) | (4.00%) | (117.13%) | (92.74%) | (232.89%) | 37.37% |
Average Days of Receivables |
82.76 | 76.36 | 91.94 | 84.70 | 81.13 | 63.27 | 91.97 | 89.28 | 95.26 | 95.70 |
Research and Development Expense of Revenue |
5.06% | 5.71% | 5.53% | 5.89% | 4.98% | 4.84% | 6.62% | 7.71% | 7.38% | 8.29% |
Selling, General and Administrative Expense of Revenue |
78.84% | 74.64% | 30.38% | 36.16% | 26.97% | 26.55% | 43.16% | 54.81% | 53.60% | 66.06% |
Intangible Assets out of Total Assets |
0.35 | 0.34 | 0.35 | 0.33 | 0.26 | 0.30 | 0.38 | 0.27 | 0.50 | 0.54 |
Share Based Compensation of Revenue |
1.42% | 0.94% | 1.41% | 0.84% | 0.78% | 1.18% | 2.81% | 3.64% | 2.14% | 0.74% |
Graham Net Nets |
(0.05) | (0.14) | (0.44) | (2.55) | (0.62) | (1.49) | (1.33) | (2.64) | (6.17) | (9.63) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 129.21 | 0.00 | 205.44 | 448.60 | 334.78 | 394.57 |
Earnings Yield |
(66.87%) | (36.91%) | (46.33%) | (134.97%) | (8.14%) | 4.90% | (121.82%) | (144.24%) | (320.78%) | (250.90%) |
Free Cash Flow Yield |
(42.72%) | (54.83%) | (118.02%) | (199.86%) | (20.43%) | (7.82%) | (19.31%) | (84.77%) | (90.28%) | (96.02%) |
Revenue per Share |
651.48 | 688.47 | 697.09 | 648.28 | 732.61 | 638.06 | 278.24 | 222.96 | 102.92 | 70.78 |
Operating CF per Share |
66.89 | 64.24 | 51.93 | 38.83 | 170.65 | 90.86 | (4.10) | (45.34) | (7.01) | (9.58) |
Capex per Share |
(135.79) | (104.64) | (124.94) | (84.97) | (73.26) | (59.65) | (26.60) | (10.61) | (16.83) | (10.06) |
Free Cash Flow per Share |
(68.90) | (40.40) | (73.00) | (46.14) | 97.39 | 31.21 | (30.70) | (55.95) | (23.83) | (19.64) |
Cash per Share |
504.31 | 400.05 | 217.51 | 117.56 | 196.31 | 177.83 | 29.27 | 14.48 | 8.64 | 8.31 |
Shareholders Equity per Share |
711.10 | 452.75 | 316.48 | 33.78 | (15.94) | (2.19) | (9.68) | (93.95) | (58.82) | (116.36) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
711.10 | 452.75 | 316.48 | 33.78 | (15.94) | (2.19) | (9.68) | (93.95) | (58.82) | (116.36) |
Free Cash Flow |
(10.53) | (5.82) | (10.16) | (6.44) | 13.56 | 4.55 | (6.90) | (14.26) | (14.25) | (12.15) |
Working Capital |
108.21 | 91.36 | 69.06 | 51.94 | 56.24 | (27.80) | 29.33 | 24.01 | 9.03 | (105.31) |
Capital Expenditures |
(20.76) | (15.07) | (17.39) | (11.85) | (10.20) | (8.69) | (5.98) | (2.70) | (10.06) | (6.22) |
Net Current Asset Value |
(7.38) | (15.19) | (20.94) | (54.97) | (49.32) | (46.53) | (47.61) | (44.34) | (97.35) | (141.24) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 1,873.92 | 15.77 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.21 | 0.15 | 0.18 | 0.13 | 0.10 | 0.09 | 0.10 | 0.05 | 0.16 | 0.14 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 970.16 | 4.72 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.46 | 0.90 | 0.77 | 0.53 | 0.36 | 0.46 | 0.41 | 0.94 | 0.40 | 0.51 |
Cash ROIC |
(3.77%) | (2.69%) | (6.49%) | (5.22%) | 10.71% | 3.64% | (9.00%) | (31.51%) | (20.88%) | (17.78%) |
Accounts Receivable Turnover |
4.13 | 4.58 | 4.30 | 3.98 | 4.67 | 4.79 | 3.92 | 3.83 | 4.11 | 3.18 |
Accounts Payable Turnover |
2.59 | 2.53 | 2.97 | 3.09 | 2.59 | 2.78 | 2.97 | 2.65 | 2.03 | 0.95 |
Inventory Turnover |
1.66 | 1.75 | 1.76 | 1.68 | 1.72 | 1.85 | 1.75 | 1.76 | 2.04 | 1.41 |
Average Days of Payables |
161.00 | 130.79 | 111.02 | 118.24 | 166.33 | 100.59 | 124.01 | 125.00 | 243.69 | 403.06 |
Days of Inventory on Hand |
211.93 | 209.15 | 199.35 | 223.41 | 206.55 | 193.67 | 181.50 | 194.63 | 176.29 | 255.49 |
Average Receivables |
24.09 | 21.66 | 22.59 | 22.71 | 21.83 | 19.39 | 15.93 | 14.83 | 14.98 | 13.77 |
Average Payables |
21.70 | 22.64 | 18.71 | 16.93 | 20.64 | 19.73 | 15.25 | 14.09 | 19.79 | 28.24 |
Average Inventory |
33.86 | 32.70 | 31.58 | 31.19 | 31.12 | 29.67 | 25.81 | 21.22 | 19.65 | 19.10 |
Average Assets |
306.64 | 221.28 | 172.32 | 141.37 | 130.73 | 124.65 | 105.50 | 75.77 | 81.36 | 104.23 |
Average Common Equity |
161.31 | 86.96 | 54.63 | 24.38 | 1.25 | (1.27) | (1.25) | (13.06) | (29.56) | (53.58) |
Columns are period end dates